Crossignal Therapeutics

Crossignal Therapeutics is developing new generation of small molecule anti-cancer immunotherapies. We focus on the discovery of immune cell-expressed, tumor metabolic factors (TME)-targeted GPCRs (TMERs) and design our drug candidates by testing their ability to inhibit critical pathways in TME-mediated cancer immune escape. We are driven by our deep-rooted experience in immunology & oncology, GPCR signal transduction, and drug discovery to develop a whole new generation of IO therapeutics.